Sorrento Therapeutics Inc (SRNE)

[dia76ca]

The phase 2/3 study of oral ABIVERTINIB in treating ARDS in Covid patients is important. Apparently the phase 2b will be to identify the most effective dose level. If they can identify an even better dose level than was used in the previous two phase 2 trials that would be great! Nice to see it will take place in the US, Mexico and Brazil. They already have hospital connections in all three countries.
They have already identified that the sweet spot for the use of ABIVERTINIB is in patients requiring oxygen support by non-invasive ventilation or high flow oxygen. This portion of the patient population were shown to be up to 5-fold more likely to benefit than those requiring low flow supplementation.
Covid ARDS and non-Covid ARDS are a very large unmet medical need. An oral treatment would be very useful and affordable!